Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

BIZARRE: 3 - You Need To See This

Forget About SAFE Plus Or CLIMB Act As Cannabis Stock Catalysts, With Canopy's Potential Exception

Canopy Growth Corporation (NASDAQ: CGC)

Benzinga · Nov 7, 2022

This Is How It's Done: Why Is Canopy's US Consolidation Plan Blueprint For Other Canadian Cannabis LPs

Canadian cannabis giant Canopy Growth Corporation (NASDAQ: CGC) (TSX:WEED) announced its intention to consolidate in the US via a new holding company dubbed Canopy

Benzinga · Oct 26, 2022

3 Cannabis Stocks Going up in Flames to Avoid

The wide use of cannabis for recreational activities and its increased medicinal use has helped the market gain traction over the past years. However, with legalization barriers worldwide, this industry is in an odd limbo in which consumption flourishes, but penalties and taxes still prevail. Given the backdrop, it should…

StockNews.com · Aug 30, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Canopy Growth Stock Slides, Analysts Divided

Canopy Growth (NASDAQ: CGC) experienced a severe sell-off, as it currently trades at the very bottom of its 52-week range. It's almost near the bottom on shorter time spans, including the 50-day range. The stock is currently down -74.62%, severely underperforming the S&P 500 with a loss of -18.25%.

Benzinga · Jul 27, 2022

2Q Canada Recreational Cannabis Market Analysis: +21 YoY Growth Outperforming The U.S.

In a recent analyst note, Cantor Fitzgerald's Pablo Zuanic gave an overview of the Canadian recreational cannabis market in the second quarter of 2022, according to data collected by Hifyre, a leading in-shop and online digital toolset for cannabis dispensaries.

Benzinga · Jul 14, 2022

Leading Welsh glass manufacturing firm acquired in a multi-million-pound deal

Cwmtillery Glass Centre has been acquired in a deal brokered by Gambit Corporate Finance

Birmingham Post · Jul 13, 2022

2 Cannabis Stocks to Avoid After Stifel Cuts Their Price Targets

Surging inflation and the Fed’s hawkish monetary policy stance could keep the stock market under pressure in the near term. Amid the uncertainties surrounding the economy and the stock market, Stifel analysts are maintaining a negative outlook on the cannabis industry and have cut their price targets for the stocks…

StockNews.com · May 12, 2022

Read news from The Economist, FT, and more,
with one subscription

Better Buy for 2022: Sundial vs. Canopy Growth

In this article I will analyze and compare Sundial Growers (SNDL) and Canopy Growth (CGC) to determine which cannabis stock is currently the better investment.

StockNews.com · Apr 12, 2022

What Are Whales Doing With Canopy Growth

A whale with a lot of money to spend has taken a noticeably bearish stance on Canopy Growth. Looking at options history for Canopy Growth (NASDAQ:CGC) we detected 32 strange trades.

Benzinga · Apr 1, 2022

What's Going On With Tilray, Canopy Growth And Aurora Cannabis Shares Today?

Tilray Brands Inc (NASDAQ: TLRY), Canopy Growth Corp (NASDAQ: CGC) and Aurora Cannabis Inc (NASDAQ: ACB) are trading lower

Benzinga · Mar 31, 2022

Canopy Growth Whale Trades For March 28

Someone with a lot of money to spend has taken a bearish stance on Canopy Growth (NASDAQ:CGC). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Mar 28, 2022

3 Cannabis Stocks To Short Now After Getting Too High

Selling defined risk bear call spreads to get paid now to be a seller at higher prices later.

StockNews.com · Mar 27, 2022

Why Tilray, Canopy Growth Look Set For New Highs Despite Failing To Hold After-Hours Surge

Canopy Growth Corporation (NASDAQ: CGC) and Tilray, Inc (NASDAQ: TLRY) gapped up slightly higher on Wednesday after running up to 7.43% and 12.87%, respectively, in the after-hours trading session on Tuesday.

Benzinga · Mar 23, 2022

Canopy Growth's David Klein And Wana Brands' Nancy Whiteman To Keynote At Benzinga Cannabis Capital Conference

David Klein, CEO of Canopy Growth Corporation (TSX: WEED) NASDAQ: CGC)

Benzinga · Mar 18, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Mar 1, 2022

Analyst Ratings For Canopy Gwth

Over the past 3 months, 5 analysts have published their opinion on Canopy Gwth (NASDAQ:CGC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

StockNews.com · Feb 17, 2022

Is Canopy Growth a Smart Cannabis Stock to Own in 2022?

Shares of smart cannabis company Canopy Growth (CGC) have retreated in price significantly over the past few months. However, given that the company recently launched new products across its brand portfolio, is it worth betting on the stock now? Read on, let's find out.

Benzinga · Feb 1, 2022

Canopy Growth's BioSteel Sells Sports Drinks To Nearly 15,000 Stores Across U.S.

BioSteel Sports Nutrition Inc., which is part-owned by Canopy Growth Corporation (NASDAQ: CGC) announced a series of new deals with retailers that bring the brand’s lineup of Clean. Healthy. Hydration.

StockNews.com · Jan 28, 2022

4 Overvalued Cannabis Stocks Investors Should Continue to Avoid

The cannabis industry witnessed solid growth last year on a legalization wave and increasing demand for innovative cannabis products. But while the industry is expected to maintain its momentum this year, some cannabis stocks are trading at lofty valuations despite their companies’ relatively weak growth prospects. So, we think overvalued…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com · Jan 19, 2022

Canopy Growth vs. OrganiGram: Which Cannabis Stock Is a Better Buy?

Canadian cannabis producers such as Canopy Growth (CGC) and OrganiGram (OGI) have trailed the broader markets in the last three years. The two companies have been negatively impacted by a slew of macro-economic and industry-specific headwinds. But can they derive outsized gains to investors in 2022?.

1 2 3

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical – Pharmaceuticals

69 stories

Canopy Growth Corporation

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.